No Data
No Data
No Data
No Data
No Data
Alport Syndrome Pipeline Insight 2024, Featuring Eloxx Pharmaceuticals, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics and Reata Pharmaceuticals
Yahoo FinanceApr 11 23:04
Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative
TipRanksMar 30 04:22
Almirall and Eloxx Pharmaceuticals Enter Into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I read
BusinesswireMar 13 23:33
Almirall Signs License Deal With Eloxx Pharmaceuticals for Skin Diseases Treatment
Almirall (ALM.MC) signed an exclusive license agreement with Eloxx Pharmaceuticals for the latter's skin disease treatment candidate ZKN-013. The Spanish pharmaceutical company will secure the rights
MT NewswiresMar 13 17:02
Eloxx Pharmaceuticals 3Q Loss/Shr $1.31 >ELOX
Eloxx Pharmaceuticals 3Q Loss/Shr $1.31 >ELOX
Dow JonesNov 14, 2023 05:15
Press Release: Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent wi
Dow JonesNov 14, 2023 05:15
No Data
No Data